After grabbing 0.57 million shares, the institutional investor is now in possession of 0.57 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.83% having worth around $79537.0. Moreover, Two Sigma Investments LP increased its share by 0.43 million to have a control over 0.43 million shares. And Telemetry Investments LLC raised its holdings to 0.28 million shares by acquiring 0.4 million shares or 0.58% of the stake.
Vascular Biogenics Ltd. (VBLT) concluded trading on 11/23/22 at a closing price of $0.15, with 4.47 million shares of worth about $0.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -90.95% during that period and on Wednesday the price saw a gain of about 9.75%. Currently the company’s common shares owned by public are about 77.40M shares, out of which, 53.76M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the VBLT stock and their offered price forecasts bring an average price target of $5.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $5.00 and could fall to a lowest price of $5.00. The stock’s current price level is 97.0% above of average price target set by the analysts, while a rise to estimated low would result in gain of 97.0% for the stock. However, touching the estimated high of $5.00 would mean a gain of 97.0% for the stock.
Delaware Healthcare Fund, Fidelity Nasdaq Composite Index F, and Gestion Boutique IV FI – Gesem W- are the top 3 mutual funds which are holding stakes in Vascular Biogenics Ltd. Delaware Healthcare Fund is currently holding 0.2 million shares of worth totaling $27800.0. The company recently came buying 0.0 shares which brought its stake up to 0.29% of the company’s outstanding shares. Gestion Boutique IV FI – Gesem W-, after buying 11016.0 shares, have now control over 0.02% of the stake in the company. It holds 48.0 shares of worth $1531.0.
However, the stock later moved at a day high price of 0.1630, or with a gain of 9.75%. Stock saw a price change of 12.59% in past 5 days and over the past one month there was a price change of 8.49%. Year-to-date (YTD), VBLT shares are showing a performance of -92.28% which decreased to -92.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.11 but also hit the highest price of $2.38 during that period. The average intraday trading volume for Vascular Biogenics Ltd. shares is 1.47 million. The stock is currently trading 17.27% above its 20-day simple moving average (SMA20), while that difference is up 4.52% for SMA50 and it goes to -83.93% lower than SMA200.
Acadian Asset Management LLC acquired 0.57 million shares of Vascular Biogenics Ltd. having value of about $79537.0. Vascular Biogenics Ltd. (NASDAQ: VBLT) currently have 77.40M outstanding shares and institutions hold larger chunk of about 17.10% of that. Holding of mutual funds in the company is about 4.49% while other institutional holders and individual stake holders have control over 7.01% and 0.37% of the stake respectively.
The stock has a current market capitalization of $10.67M and its 3Y-monthly beta is at 0.62. It has posted earnings per share of -$0.47 in the same period. It has Quick Ratio of 4.10 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VBLT, volatility over the week remained 11.45% while standing at 10.75% over the month.
Analysts are in expectations that Vascular Biogenics Ltd. (VBLT) stock would likely to be making an EPS of -$0.11 in the current quarter, while forecast for next quarter EPS is -$0.09 and it is -$0.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.11 which is -$0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.09 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 18.70% while it is estimated to increase by 24.40% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Vascular Biogenics Ltd. (VBLT)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.00. Out of those 1 Wall Street analysts, 0 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
On July 18, 2022, Oppenheimer Resumed their recommendations, while on April 28, 2022, Chardan Capital Markets Initiated their ratings for the stock with a price target of $5. Stock get a Buy rating from Guggenheim on May 18, 2021.